FlexOnTheGrind
New member
I wanted to bring attention to a key issue regarding anabolic androgenic steroids (AAS) and their impact on liver health, specifically focusing on hepatotoxicity linked to these substances when used as dietary supplements. I'll be digging through Meso to compile relevant posts on this subject and will update this thread with the information. If anyone knows of additional studies or posts that should be included, feel free to share!
One notable study I came across is titled:
El Sherrif Y, Potts JR, Howard MR, et al. Hepatotoxicity from anabolic androgenic steroids marketed as dietary supplements: Contribution from ATP8B1/ABCB11 mutations?
Liver International, 2013
[Link to study](https://www.wiley.com)
Key Points from the Study:
- Background : While the possession and use of anabolic steroids are illegal without a prescription, non-prescription use of AAS remains widespread, particularly in the context of bodybuilding and athletic performance enhancement.
- Case Study Overview : The study examines two cases of Caucasian males (aged 25 and 45) who developed cholestatic hepatitis after using a dietary supplement called Mass-Drol, which contains the AAS 2alpha-17alpha-dimethyl-etiocholan-3-one,17beta-ol.
- Findings : Despite severe hyperbilirubinemia, the gamma-glutamyl transferase (GGT) levels remained normal. Liver biopsies revealed signs of cholestasis, with both patients showing deficiencies in canalicular enzyme expression, particularly ATP8B1 and ABCB11. These are key proteins involved in bile transport, and abnormalities in their expression can lead to cholestatic conditions.
- Genetic Factors : The younger patient was heterozygous for a mutation (c.2093G>A) in the ABCB11 gene, which has previously been linked to drug-induced liver injury. This mutation may have contributed to the hepatotoxicity seen in these cases.
- Conclusion : The use of AAS marketed as dietary supplements continues to pose a significant risk for liver toxicity. This study suggests that genetic factors, such as mutations in ATP8B1 and ABCB11, could play a role in how these substances cause liver damage, possibly unmasking underlying genetic cholestatic syndromes.
This research highlights the risks of using unregulated AAS, especially in supplement form, and the potential for severe liver damage. It's important to understand the genetic and biochemical mechanisms behind this toxicity, as well as the long-term health implications.
One notable study I came across is titled:
El Sherrif Y, Potts JR, Howard MR, et al. Hepatotoxicity from anabolic androgenic steroids marketed as dietary supplements: Contribution from ATP8B1/ABCB11 mutations?
Liver International, 2013
[Link to study](https://www.wiley.com)
Key Points from the Study:
- Background : While the possession and use of anabolic steroids are illegal without a prescription, non-prescription use of AAS remains widespread, particularly in the context of bodybuilding and athletic performance enhancement.
- Case Study Overview : The study examines two cases of Caucasian males (aged 25 and 45) who developed cholestatic hepatitis after using a dietary supplement called Mass-Drol, which contains the AAS 2alpha-17alpha-dimethyl-etiocholan-3-one,17beta-ol.
- Findings : Despite severe hyperbilirubinemia, the gamma-glutamyl transferase (GGT) levels remained normal. Liver biopsies revealed signs of cholestasis, with both patients showing deficiencies in canalicular enzyme expression, particularly ATP8B1 and ABCB11. These are key proteins involved in bile transport, and abnormalities in their expression can lead to cholestatic conditions.
- Genetic Factors : The younger patient was heterozygous for a mutation (c.2093G>A) in the ABCB11 gene, which has previously been linked to drug-induced liver injury. This mutation may have contributed to the hepatotoxicity seen in these cases.
- Conclusion : The use of AAS marketed as dietary supplements continues to pose a significant risk for liver toxicity. This study suggests that genetic factors, such as mutations in ATP8B1 and ABCB11, could play a role in how these substances cause liver damage, possibly unmasking underlying genetic cholestatic syndromes.
This research highlights the risks of using unregulated AAS, especially in supplement form, and the potential for severe liver damage. It's important to understand the genetic and biochemical mechanisms behind this toxicity, as well as the long-term health implications.
